AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9859922 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae DNA detection in coronary revascularization samples
Number of subjects: 238
Study 9859922 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae DNA detection in carotid artery stenosis samples
Number of subjects: 238
Study 9859922 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae DNA detection in aorta samples
Number of subjects: 238
Study 9859922 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae DNA detection in iliac artery samples
Number of subjects: 238
Study 9859922 — intervention group
Group type: COMPARATOR
Intervention: Non-atherosclerotic control samples
Number of subjects: 238
Study 7622969 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear communication instructions (n = 30)
Number of subjects: 61
Study 7622969 — intervention group
Group type: COMPARATOR
Intervention: Unclear communication instructions (n = 31)
Number of subjects: 61
Study 2883104 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 and 0.2 mg)
Number of subjects: 10
Study 2883104 — intervention group
Group type: EXPERIMENTAL
Intervention: S 3341 (1 and 2 mg)
Number of subjects: 10
Study 2883104 — intervention group
Group type: COMPARATOR
Intervention: Clonidine and S 3341
Number of subjects: 10
Study 31977878 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent treatment program for 12 weeks
Number of subjects: 56
Study 31977878 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment for 12 weeks
Number of subjects: 56
Study 30564798 — intervention group
Group type: COMPARATOR
Intervention: Direct restoration with composite (C)
Number of subjects: 72
Study 30564798 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct restoration with composite and additional glass‐fiber post (CP)
Number of subjects: 72
Study 30564798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic veneer restoration (V)
Number of subjects: 72
Study 30564798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic veneer restoration and additional glass‐fiber post (VP)
Number of subjects: 72
Study 30564798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic crown restoration (Cr)
Number of subjects: 72
Study 30564798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic crown restoration and additional glass‐fiber post (CrP)
Number of subjects: 72
Study 27484173 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple Calculation and Reading Aloud intervention (SCRA)
Number of subjects: 0
Study 27484173 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 0
Study 24954843 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol administration (20mg intravenously) before retrieval
Number of subjects: 0
Study 24954843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24954843 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol administration before encoding
Number of subjects: 0
Study 22215031 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual exercise targeting strength
Number of subjects: 25
Study 22215031 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual exercise targeting endurance
Number of subjects: 25
Study 22215031 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual exercise targeting power
Number of subjects: 25
Study 22215031 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual exercise targeting speed
Number of subjects: 25
Study 22215031 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 25
Study 20394322 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Flex (dip level 2)
Number of subjects: 76
Study 20394322 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 76
Study 20394322 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Flex
Number of subjects: 76
Study 18212283 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil
Number of subjects: 2078
Study 18212283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2078
Study 18821106 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct therapy
Number of subjects: 0
Study 18821106 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect therapy
Number of subjects: 0
Study 18821106 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual therapy
Number of subjects: 0
Study 18821106 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy
Number of subjects: 0
Study 18821106 — intervention group
Group type: COMPARATOR
Intervention: Usual levels of community‐based speech‐and‐language therapy
Number of subjects: 0
Study 15353155 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) treatment for 1-4 weeks
Number of subjects: 2793
Study 11810350 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS SM1AKS 80 Hz 6 mA
Number of subjects: 30
Study 11810350 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS SM1AKS 80 Hz 0 mA
Number of subjects: 30
Study 9250304 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% acetic acid applied before the smear
Number of subjects: 42
Study 9250304 — intervention group
Group type: COMPARATOR
Intervention: Control group (acetic acid applied after the smear)
Number of subjects: 42
Study 8326055 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit weight training for 4 months
Number of subjects: 43
Study 8326055 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 43
Study 3826809 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral phenytoin capsules (18 mg/kg)
Number of subjects: 44
Study 3826809 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral phenytoin suspension (18 mg/kg)
Number of subjects: 44
Study 3826809 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral phenytoin (both forms)
Number of subjects: 44
Study 977729 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 12
Study 977729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30730214 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-of-charge subdermal etonogestrel implant (SEI)
Number of subjects: 265
Study 30730214 — intervention group
Group type: COMPARATOR
Intervention: Partially paid subdermal etonogestrel implant (SEI)
Number of subjects: 265
Study 30730214 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-of-charge and partially paid subdermal etonogestrel implant (SEI)
Number of subjects: 265
Study 28349730 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO (7.5% CHO; 5 mL · kg‐1 per exercise session; n = 6)
Number of subjects: 12
Study 28349730 — intervention group
Group type: COMPARATOR
Intervention: PLA (0% CHO, taste- and volume-matched solution; n = 6)
Number of subjects: 12
Study 28349730 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO
Number of subjects: 12
Study 28349730 — intervention group
Group type: COMPARATOR
Intervention: PLA
Number of subjects: 12
Study 28349730 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO and PLA
Number of subjects: 12
Study 26717860 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPT (once daily at 0.17 mg/kg/d)
Number of subjects: 543
Study 26717860 — intervention group
Group type: COMPARATOR
Intervention: IR-Tac (twice daily at 0.1 mg/kg/d)
Number of subjects: 543
Study 26717860 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPT
Number of subjects: 543
Study 26717860 — intervention group
Group type: COMPARATOR
Intervention: IR-Tac
Number of subjects: 543
Study 25217464 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cardiac rehabilitation program ('ActivateYourHeart') for 6 weeks.
Number of subjects: 94
Study 25217464 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 94
Study 21671144 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency rTMS (20 Hz)
Number of subjects: 45
Study 21671144 — intervention group
Group type: COMPARATOR
Intervention: Low frequency rTMS (1 Hz)
Number of subjects: 45
Study 21671144 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 45
Study 20018274 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (Group 2)
Number of subjects: 60
Study 20018274 — intervention group
Group type: COMPARATOR
Intervention: Control (Group 1)
Number of subjects: 60
Study 20018274 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiolytics (Group 3)
Number of subjects: 60
Study 18186583 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at acupoints selected by thermogram (temperature difference > 0.5 degrees C from healthy side)
Number of subjects: 180
Study 18186583 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at conventionally selected acupoints
Number of subjects: 180
Study 18186583 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at acupoints selected by thermogram
Number of subjects: 180
Study 15102874 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg/day FTY720
Number of subjects: 60
Study 15102874 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day FTY720
Number of subjects: 60
Study 15102874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12226034 — intervention group
Group type: EXPERIMENTAL
Intervention: IV preparation (80 mg in 2 mL vial diluted with 2 mL saline containing preservatives)
Number of subjects: 19
Study 12226034 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free preparation (300 mg in 5 mL solution)
Number of subjects: 19
Study 12226034 — intervention group
Group type: COMPARATOR
Intervention: IV preparation
Number of subjects: 19
Study 12226034 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free preparation
Number of subjects: 19
Study 9839330 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen administration before hepatic DSA
Number of subjects: 0
Study 8205580 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Platinum Professional Toothwhitening System
Number of subjects: 50
Study 8205580 — intervention group
Group type: COMPARATOR
Intervention: Rembrandt Lighten Bleaching Gel
Number of subjects: 50
Study 2732125 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rifampicin 900 mg/day plus oral doxycycline 200 mg/day for 45 days (Regimen A)
Number of subjects: 143
Study 2732125 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doxycycline 200 mg/day for 45 days plus im streptomycin 1 g/day for 21 days (Regimen B)
Number of subjects: 143
Study 2732125 — intervention group
Group type: COMPARATOR
Intervention: WHO regimen combining oral tetracycline 2 g/day for 21 days plus im streptomycin 1 g/day for 14 days (Regimen C)
Number of subjects: 143
Study 29713463 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (303 children)
Number of subjects: 604
Study 29713463 — intervention group
Group type: COMPARATOR
Intervention: Placebo (301 children)
Number of subjects: 604
Study 29713463 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (121 children, subgroup)
Number of subjects: 604
Study 29713463 — intervention group
Group type: COMPARATOR
Intervention: Placebo (121 children, subgroup)
Number of subjects: 604
Study 28954791 — intervention group
Group type: EXPERIMENTAL
Intervention: Mii-vitaliSe intervention (Nintendo Wii) for 12 months
Number of subjects: 30
Study 28954791 — intervention group
Group type: COMPARATOR
Intervention: Mii-vitaliSe intervention (Nintendo Wii) after a 6-month wait for 6 months
Number of subjects: 30
Study 26159140 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-Care-Robot Program (conducted twice a week for 5 weeks)
Number of subjects: 42
Study 26159140 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 42
Study 23180349 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT/leucovorin/irinotecan (TEGAFIRI)
Number of subjects: 49
Study 23180349 — intervention group
Group type: COMPARATOR
Intervention: UFT/leucovorin/oxaliplatin (TEGAFOX)
Number of subjects: 49
Study 23180349 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response
Number of subjects: 49
Study 23180349 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free and overall survival
Number of subjects: 49
Study 21600084 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of compound azintamid (2 tablets 3 times a day) and domperidone (10 mg 3 times a day) for 4 weeks
Number of subjects: 208
Study 21600084 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of compound azintamid and domperidone
Number of subjects: 208
Study 21600084 — intervention group
Group type: COMPARATOR
Intervention: Domperidone (10 mg 3 times a day) for 4 weeks
Number of subjects: 208
Study 18462076 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention aimed at reducing HIV-related stigma, conveyed through participatory small group activities (role-plays, games, group discussions, testimony by an HIV advocate).
Number of subjects: 138
Study 18462076 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified in detail).
Number of subjects: 138
Study 16950470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 22
Study 12201926 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week dietary intervention
Number of subjects: 0
Study 12201926 — intervention group
Group type: COMPARATOR
Intervention: Prostate biopsy trauma
Number of subjects: 0
Study 10326889 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-containing oral contraceptive minipills (30 mirog)
Number of subjects: 31
Study 10326889 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-releasing intrauterine contraceptive system (LNG-IUS)
Number of subjects: 31
Study 10326889 — intervention group
Group type: COMPARATOR
Intervention: Copper-releasing intrauterine device (IUD)
Number of subjects: 31
Study 8953976 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular scatter ('grid') laser photocoagulation
Number of subjects: 103
Study 8953976 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 103
Study 1778327 — intervention group
Group type: EXPERIMENTAL
Intervention: JNIH-7 (mono-component vaccine)
Number of subjects: 0
Study 1778327 — intervention group
Group type: EXPERIMENTAL
Intervention: JNIH-6 (two-component vaccine)
Number of subjects: 0
Study 7095559 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone/azathioprine therapy
Number of subjects: 30
Study 7095559 — intervention group
Group type: COMPARATOR
Intervention: no therapy (control group)
Number of subjects: 30
Study 31914940 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin, 600 mg daily for 6 weeks
Number of subjects: 880
Study 31914940 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (riboflavin)
Number of subjects: 880
Study 30935657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocriplasmin (0.125 mg intravitreal injection)
Number of subjects: 480
Study 28881220 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 28881220 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily life EF behavior
Number of subjects: 0
Study 28881220 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based CBT
Number of subjects: 0
Study 28881220 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 26366278 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C 0.1% injected submucosally after IOU
Number of subjects: 151
Study 26366278 — intervention group
Group type: COMPARATOR
Intervention: IOU only (Control)
Number of subjects: 151
Study 26255546 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (200 mg/d)
Number of subjects: 70
Study 26255546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 22987921 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight
Number of subjects: 418
Study 22987921 — intervention group
Group type: EXPERIMENTAL
Intervention: Current pulse pressure
Number of subjects: 418
Study 22987921 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity level
Number of subjects: 418
Study 22987921 — intervention group
Group type: EXPERIMENTAL
Intervention: Current weight
Number of subjects: 418
Study 22987921 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 418
Study 22987921 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal relative wall thickness and increased left ventricular mass index (eccentric remodeling)
Number of subjects: 418
Study 22987921 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in both normal relative wall thickness and left ventricular mass index (concentric, increased LVM)
Number of subjects: 418
Study 19372453 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamins
Number of subjects: 505
Study 19372453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 505
Study 17321928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.15 mg/kg IV
Number of subjects: 360
Study 17321928 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 360
Study 15138439 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine (0.15 mg/kg)
Number of subjects: 7
Study 11438499 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 40
Study 11438499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9146783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 23
Study 9146783 — intervention group
Group type: EXPERIMENTAL
Intervention: Tauro-ursodeoxycholic acid
Number of subjects: 23
Study 7525515 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (40-50 Gy)
Number of subjects: 88
Study 7525515 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy (Control)
Number of subjects: 88
Study 7525515 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 88
Study 2438923 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirmenol hydrochloride (200 to 400 mg daily)
Number of subjects: 196
Study 31843426 — intervention group
Group type: COMPARATOR
Intervention: Sham positive airway pressure (4 cmH2O)
Number of subjects: 156
Study 31843426 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometry, airway clearance, mobilisation, and sham positive pressure (4 cmH2O)
Number of subjects: 156
Study 31843426 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometry, airway clearance, mobilisation, and positive airway pressure (15 cmH2O)
Number of subjects: 156
Study 31843426 — intervention group
Group type: COMPARATOR
Intervention: Control group with sham positive airway pressure (4 cmH2O)
Number of subjects: 156
Study 30767298 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 271
Study 28539539 — intervention group
Group type: EXPERIMENTAL
Intervention: Bococizumab 50 mg
Number of subjects: 218
Study 28539539 — intervention group
Group type: EXPERIMENTAL
Intervention: Bococizumab 100 mg
Number of subjects: 218
Study 28539539 — intervention group
Group type: EXPERIMENTAL
Intervention: Bococizumab 150 mg
Number of subjects: 218
Study 28539539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 28539539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg daily
Number of subjects: 218
Study 24911019 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with low PA in men: age, being divorced or separated, still working, having a weak social network, poor diet, and a health professional's suggestion to increase PA.
Number of subjects: 1303
Study 24911019 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with low PA in women: cardiovascular disease and depressive symptoms.
Number of subjects: 1303
Study 23438223 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% maltodextrin (CHO) mouth rinse
Number of subjects: 12
Study 23438223 — intervention group
Group type: COMPARATOR
Intervention: Taste-matched placebo (PLB) solution
Number of subjects: 12
Study 22097205 — intervention group
Group type: EXPERIMENTAL
Intervention: Education about clinical research
Number of subjects: 258
Study 22097205 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 258
Study 19188925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ghrelin (5 pmol kg(‐1) min(‐1))
Number of subjects: 26
Study 16507585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fontolizumab 4 mg/kg
Number of subjects: 133
Study 16507585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fontolizumab 10 mg/kg
Number of subjects: 133
Study 16507585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 15640628 — intervention group
Group type: EXPERIMENTAL
Intervention: Afelimomab 1 mg/kg for 3 days
Number of subjects: 2634
Study 15640628 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 days
Number of subjects: 2634
Study 11385886 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort
Number of subjects: 0
Study 11385886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9282480 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern-reversal visual evoked potentials (PRVEP's) analysis using quadratic spline wavelet
Number of subjects: 0
Study 8298071 — intervention group
Group type: EXPERIMENTAL
Intervention: Fadrozole hydrochloride (12 mg dose) administered after a standardized meal
Number of subjects: 9
Study 8298071 — intervention group
Group type: COMPARATOR
Intervention: Fadrozole hydrochloride (12 mg dose) administered after fasting for 12 hours
Number of subjects: 9
Study 3106096 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 100 mg for 5 days
Number of subjects: 10
Study 3106096 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (2 mg intravenous bolus followed by 1.6 mg/hour for 9 hours)
Number of subjects: 10
Study 3106096 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study 2661789 — intervention group
Group type: EXPERIMENTAL
Intervention: MBDL regimen (metoclopramide 8 mg/kg, benztropine 0.04 mg/kg, dexamethasone 0.7 mg/kg, lorazepam 0.1 mg/kg)
Number of subjects: 26
Study 2661789 — intervention group
Group type: EXPERIMENTAL
Intervention: MBDL regimen
Number of subjects: 26
Study 2661789 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (3.3 mg/kg in four doses over 24 hours)
Number of subjects: 26